Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

177Lu-PSMA-617

Name
177Lu-PSMA-617
Target
high PSMA expression
FDA Approved
No
Ema approved
Status
0

3 clinical trials

1 drug

1 abstract

2 indications

Indication
Prostate Cancer
Indication
Metastatic Castration-resistant Prostate Cancer
Drug
177Lu-PSMA-617
Clinical trial
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2022-10-03
Clinical trial
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status: Completed, Estimated PCD: 2021-01-27
Clinical trial
Managed Access Program (MAP) Cohort Treatment Plan [CAAA617A12001M] to Provide Access to 177Lu-PSMA-617 for Patients With Metastatic Castration-resistant Prostate Cancer.
Status:
Abstract
LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).
Org: Sir Peter MacCallum Department of Oncology, St. Vincent's Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Radiation Oncology, St. Vincent's Medical School,